WASHINGTON, April 12, 2019 /PRNewswire/ — The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinical and research programs at the 29th annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) to be held April 13 – 16 in Amsterdam, Netherlands.
ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases.
“AWG is excited that data from our member companies covering a broad spectrum of infectious disease topics will be presented at ECCMID 2019,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer of Paratek Pharmaceuticals and Chairman of the AWG. “Representatives from AWG companies will be participating in over 70 different oral sessions and poster presentations, along with integrated symposiums and industry panel discussions, showcasing developments in antifungal, antibacterial, and non-traditional therapies. Their efforts represent our coalition’s sustained commitment to antimicrobial innovation and our dedication to developing life-saving treatments for patients in need.”
The following AWG member companies will be presenting at ECCMID 2019: Amplyx Pharmaceuticals, Cidara Therapeutics, Contrafect Corporation, Entasis Therapeutics, Iterum Therapeutics, Melinta Therapeutics, Motif Bio, Nabriva Therapeutics, Paratek Pharmaceuticals, SCYNEXIS, Summit Therapeutics, and VenatoRx Pharmaceuticals.
For more information on AWG member company presentations and access to specific abstracts, please visit: www.antimicrobialsworkinggroup.org/eccmid-2019/
About The Antimicrobials Working Group
AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging infectious disease companies. Today, AWG is comprised of fourteen antimicrobials companies: Amplyx Pharmaceuticals, Aridis Pharmaceuticals, Cidara Therapeutics Inc. (NASDAQ: CDTX), ContraFect Corporation (NASDAQ: CFRX), Entasis Therapeutics Inc. (NASDAQ: ETTX), Iterum Therapeutics Ltd. (NASDAQ: ITRM), Melinta Therapeutics Inc. (NASDAQ: MLNT), Motif Bio PLC (AIM/NASDAQ: MTFB) , Nabriva Therapeutics US Inc. (NASDAQ: NBRV), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), Qpex Biopharma, Inc., SCYNEXIS Inc. (NASDAQ: SCYX), Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM), and VenatoRx Pharmaceuticals, Inc.
For more information, visit: www.antimicrobialsworkinggroup.org
About The Conafay Group
The Conafay Group, led by Stephen R. Conafay, Principal, is a life-sciences government relations firm based in Washington D.C. that serves as Washington counsel and coalition manager for AWG.
For more information, visit: www.conafaygroup.com
SOURCE Antimicrobials Working Group (AWG)